Compare EOI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
| Metric | EOI | KURA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.7M | 744.0M |
| IPO Year | 2004 | 2015 |
| Metric | EOI | KURA |
|---|---|---|
| Price | $18.12 | $7.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $25.88 |
| AVG Volume (30 Days) | 68.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $62.31 |
| Revenue Next Year | N/A | $58.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $15.50 | $5.41 |
| 52 Week High | $21.58 | $12.49 |
| Indicator | EOI | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 22.53 | 36.89 |
| Support Level | N/A | $7.36 |
| Resistance Level | $20.90 | $10.50 |
| Average True Range (ATR) | 0.28 | 0.38 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 0.48 | 3.21 |
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.